Big Biologics Bet: China’s Innovent Gets $100m Financing
This article was originally published in PharmAsia News
Executive Summary
A record-breaking private financing for a Chinese biotech has seen bets placed on Suzhou-based Innovent Bio, which has 10 monoclonal antibodies including four biosimilars in its pipeline.